Fedratinib

Fedratinib, sold under the brand name Inrebic, is an anti-cancer medication used to treat myeloproliferative diseases including myelofibrosis.[3] It is used in the form of fedratinib hydrochloride capsules that are taken by mouth. It is a semi-selective inhibitor of Janus kinase 2 (JAK-2).[3][4] It was approved by the FDA on 16 August 2019.[3] Myelofibrosis is a myeloid cancer associated with anemia, splenomegaly, and constitutio... [wikipedia]